rs571617007
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 4P and 2B. PM1PM2BP4_Moderate
The NM_018941.4(CLN8):c.386G>A(p.Arg129Gln) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000589 in 1,614,106 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 13/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_018941.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CLN8 | NM_018941.4 | c.386G>A | p.Arg129Gln | missense_variant | 2/3 | ENST00000331222.6 | NP_061764.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CLN8 | ENST00000331222.6 | c.386G>A | p.Arg129Gln | missense_variant | 2/3 | 1 | NM_018941.4 | ENSP00000328182.4 | ||
KBTBD11-OT1 | ENST00000635855.1 | n.386G>A | non_coding_transcript_exon_variant | 2/30 | 5 | ENSP00000489726.1 |
Frequencies
GnomAD3 genomes AF: 0.0000657 AC: 10AN: 152096Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000119 AC: 30AN: 251482Hom.: 0 AF XY: 0.000147 AC XY: 20AN XY: 135918
GnomAD4 exome AF: 0.0000581 AC: 85AN: 1461892Hom.: 0 Cov.: 32 AF XY: 0.0000701 AC XY: 51AN XY: 727246
GnomAD4 genome AF: 0.0000657 AC: 10AN: 152214Hom.: 0 Cov.: 32 AF XY: 0.0000806 AC XY: 6AN XY: 74422
ClinVar
Submissions by phenotype
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Oct 27, 2017 | The R129Q variant has not been published as a pathogenic variant, nor has it been reported as a benign variant to our knowledge. This variant is observed in11/25792 (0.04%) alleles from individuals of European background, in large population cohorts (Lek et al., 2016). The R129Q variant is a semi-conservative amino acid substitution, which may impact secondary protein structure asthese residues differ in some properties. However, this substitution occurs at a position that is not conserved, and insilico analysis predicts this variant likely does not alter the protein structure/function. Therefore, based on the currently available information, it is unclear whether this variant is a pathogenic variant or a rare benign variant. - |
Neuronal ceroid lipofuscinosis 8 Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | Natera, Inc. | Jul 10, 2020 | - - |
Neuronal ceroid lipofuscinosis Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 11, 2023 | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 129 of the CLN8 protein (p.Arg129Gln). This variant is present in population databases (rs571617007, gnomAD 0.04%). This variant has not been reported in the literature in individuals affected with CLN8-related conditions. ClinVar contains an entry for this variant (Variation ID: 421797). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt CLN8 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at